- Home
- DNUT vs PRAX Comparison
DNUT vs PRAX Comparison
Compare DNUT & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNUT
- PRAX
- Stock Information
- Founded
- DNUT 1937
- PRAX 2015
- Country
- DNUT United States
- PRAX United States
- Employees
- DNUT N/A
- PRAX N/A
- Industry
- DNUT Food Chains
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- DNUT Consumer Staples
- PRAX Health Care
- Exchange
- DNUT Nasdaq
- PRAX Nasdaq
- Market Cap
- DNUT 739.0M
- PRAX 599.7M
- IPO Year
- DNUT 2021
- PRAX 2020
- Fundamental
- Price
- DNUT $2.73
- PRAX $38.35
- Analyst Decision
- DNUT Buy
- PRAX Strong Buy
- Analyst Count
- DNUT 8
- PRAX 10
- Target Price
- DNUT $10.58
- PRAX $116.50
- AVG Volume (30 Days)
- DNUT 5.9M
- PRAX 421.5K
- Earning Date
- DNUT 05-08-2025
- PRAX 05-02-2025
- Dividend Yield
- DNUT 5.15%
- PRAX N/A
- EPS Growth
- DNUT N/A
- PRAX N/A
- EPS
- DNUT N/A
- PRAX N/A
- Revenue
- DNUT $1,597,883,000.00
- PRAX $8,122,000.00
- Revenue This Year
- DNUT N/A
- PRAX N/A
- Revenue Next Year
- DNUT $9.87
- PRAX $789.73
- P/E Ratio
- DNUT N/A
- PRAX N/A
- Revenue Growth
- DNUT N/A
- PRAX 270.02
- 52 Week Low
- DNUT $3.03
- PRAX $26.70
- 52 Week High
- DNUT $13.25
- PRAX $91.83
- Technical
- Relative Strength Index (RSI)
- DNUT 20.89
- PRAX 53.31
- Support Level
- DNUT $4.17
- PRAX $34.89
- Resistance Level
- DNUT $4.44
- PRAX $40.89
- Average True Range (ATR)
- DNUT 0.27
- PRAX 2.30
- MACD
- DNUT -0.06
- PRAX 0.70
- Stochastic Oscillator
- DNUT 7.50
- PRAX 57.95
About DNUT Krispy Kreme Inc.
Krispy Kreme Inc is a sweet treat brand company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in-your-mouth experience. It operates through its network of fresh Doughnut Shops, partnerships with retailers, and a growing e-commerce and delivery business. The company conducts its business through the following three reported segments: U.S., which includes all operations in the United States; International, which includes operations in the U.K., Ireland, Australia, New Zealand, Canada, Japan, and Mexico; and Market Development, which includes franchise operations across the globe. It derives maximum revenue from the U.S. segment.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.